The Herald was informed last week of a 15-year-old special-needs Chaparral High School student who is in need of a kidney ...

J.P. Morgan’s U.S. equity analysts picked their top stocks for 2025 in healthcare, selecting “the most compelling investment ...

The acquisition combines the assets and capabilities of two companies founded by a leader in the GPR68 field, Professor ...

Morgans healthcare and life sciences experts Iain Wilkie and Scott Power give Stockhead readers their top picks for 2025.

Certa's pipeline includes further programs targeting major indications such as chronic kidney disease, focal segmental glomerulosclerosis, diabetic nephropathy, and other chronic fibrotic conditions.

Travere Therapeutics' financial landscape is a mix of FDA approvals, clinical setbacks, and cash concerns, with potential for growth and revenue.

But like some others on this list, its debut was merely an entrée. A larger opportunity lies ahead, the rare kidney disease FSGS, or focal segmental glomerulosclerosis. Filspari in FSGS would be a ...

It's in late-stage development for IgA nephropathy and focal segmental glomerulosclerosis (FSGS) with initial data suggesting it may halt disease progression; 12) Teclistamab: Another drug already ...

as well as TRPC6 inhibitor BI 764198 in phase 2 for rare kidney disease focal segmental glomerulosclerosis (FSGS). In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced ...

After hours: 20 December at 19:57:27 GMT-5 ...